ĭermatologic side effects include dermatitis (8%), alopecia (3%), pruritus (1%) and urticaria (<1%).
MAKING CRACK WITH LEVAMISOLE HYDROCHLORIDE SKIN
Half of the patients experiencing skin rash discontinued therapy (7%). One analysis of 267 reports representing 6,217 patients, found that patients treated for rheumatic disorders (n=1131) reported a significantly high percentage of idiosyncratic or allergic reactions. Agranulocytosis is spontaneously reversible when treatment is discontinued.
Management of levamisole-induced agranulocytosis includes early diagnosis, discontinuation of treatment, and prevention of infection. Reports show some indication that agranulocytosis is due to a type II reaction (Coombs' classification). Leukopenia is usually not prodromal to agranulocytosis. The majority of these patients (4.5%) discontinued therapy. One analysis of 267 reports representing 6,217 patients, found that patients treated for rheumatic disorders (n=1131) reported a significantly higher rate of leukopenia and agranulocytosis (4.9%). In patients with thrombocytopenia, 1% of patients show platelet counts over 130,000/mm3, and 1% show platelet counts between 50,000 and 130,000/mm3. Transient granulocytopenia has been reported in up to 20% of treated patients. Hematologic toxicity primarily involves (sometimes fatal) agranulocytosis. Applies to levamisole: oral tablet Hematologic
0 kommentar(er)
